Skip to Content

 

Are you a pharmaceutical company seeking a reliable partner for your drug development?

Learn More

Are you looking for innovative solutions in biochemistry research?

Learn More

Horizon Discovery is a UK-based listed company (AIM Markets - HZD) with approximately 280 employees in the UK, US and Europe and over 1,600 customers in over 50 countries. As a world leader in genome editing technology, we construct cells with the genetic signature of human diseases and use these disease cell models for a wide range of high-value applications. In September 2017, we acquired the business of Dharmacon, a pioneering siRNA brand, from GE Healthcare, expanding our product portfolio.
Horizon
On March 1, 2018, we established a Japanese corporation, Horizon Discovery Co., Ltd., and began operations in Japan.

*GE Healthcare Japan Co., Ltd.'s Life Science Headquarters has been continuing operations related to Dharmacon products in Japan, and from Friday, June 1, 2018, we will be importing all Dharmacon products from Horizon Discovery Co., Ltd. Our agent, Funakoshi Co., Ltd., will take care of this for you. Please check this out for details.


 Horizon Discovery's products and services support customers in a wide range of fields, from basic research and drug discovery research to drug development, pharmaceuticals, and molecular diagnostics.

product:
We offer genome-edited cell lines, in vivo model organisms, CHO cell lines, siRNA/shRNA/microRNA, and CRISPR-Cas9 genome editing reagents. We also handle standard samples for molecular diagnosis.

service:
We offer custom creation services for cell lines and model animals. We also accept various types of screening services.